OBJECTIVE: Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare variant of HCC. We report an analysis of the clinicopathologic features, treatment outcomes, and prognostic indicators of 94 cases. METHODS: We retrospectively collected clinicopathologic and treatment outcome data from 94 FLHCC patients (48 males and 46 females). Median overall survival (OS) and recurrence-free survival (RFS) were calculated using Kaplan-Meier curves, and survival rates were compared by the log-rank test. The Cox proportional hazard model was used for univariate and multivariate estimation of hazard risk ratios and 95% confidence intervals (CI) for factors that correlated with survival and disease recurrence after resection. RESULTS: Median age was 23 years (14-75); median OS was 57.2 months (95% CI, 36.4-77.9), and median RFS was 13.9 months (95% CI, 8.8-18.9). White race, female gender, early tumor stage, and tumor resection including metastasectomy were positively associated with longer OS, while female gender was the only significant positive predictor of longer RFS. Finally, the 5-fluorouracil-interferon combination was the most frequently used systemic therapy. CONCLUSIONS: Our analyses indicate that surgical approaches including metastasectomy as the first-line treatment in FLHCC correlated with better outcome. Multimodality approaches, including neoadjuvant and adjuvant therapies, prolonged patient survival.
OBJECTIVE:Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare variant of HCC. We report an analysis of the clinicopathologic features, treatment outcomes, and prognostic indicators of 94 cases. METHODS: We retrospectively collected clinicopathologic and treatment outcome data from 94 FLHCC patients (48 males and 46 females). Median overall survival (OS) and recurrence-free survival (RFS) were calculated using Kaplan-Meier curves, and survival rates were compared by the log-rank test. The Cox proportional hazard model was used for univariate and multivariate estimation of hazard risk ratios and 95% confidence intervals (CI) for factors that correlated with survival and disease recurrence after resection. RESULTS: Median age was 23 years (14-75); median OS was 57.2 months (95% CI, 36.4-77.9), and median RFS was 13.9 months (95% CI, 8.8-18.9). White race, female gender, early tumor stage, and tumor resection including metastasectomy were positively associated with longer OS, while female gender was the only significant positive predictor of longer RFS. Finally, the 5-fluorouracil-interferon combination was the most frequently used systemic therapy. CONCLUSIONS: Our analyses indicate that surgical approaches including metastasectomy as the first-line treatment in FLHCC correlated with better outcome. Multimodality approaches, including neoadjuvant and adjuvant therapies, prolonged patient survival.
Authors: Howard M Katzenstein; Mark D Krailo; Marcio H Malogolowkin; Jorge A Ortega; Wenchun Qu; Edwin C Douglass; James H Feusner; Marleta Reynolds; John J Quinn; Kurt Newman; Milton J Finegold; Joel E Haas; Martha G Sensel; Robert P Castleberry; Laura C Bowman Journal: Cancer Date: 2003-04-15 Impact factor: 6.860
Authors: Sanjay Kakar; Lawrence J Burgart; Kenneth P Batts; Joaquin Garcia; Dhanpat Jain; Linda D Ferrell Journal: Mod Pathol Date: 2005-11 Impact factor: 7.842
Authors: G El-Gazzaz; W Wong; M K El-Hadary; B K Gunson; D F Mirza; A D Mayer; J A Buckels; P McMaster Journal: Transpl Int Date: 2000 Impact factor: 3.782
Authors: Gabriel G Malouf; Laurence Brugières; Marie-Cécile Le Deley; Sandrine Faivre; Monique Fabre; Valérie Paradis; Isabelle Aerts; Christophe Le Tourneau; Chantal Dreyer; Sophie Branchereau; Jacques Belghiti; Eric Raymond Journal: Cancer Date: 2012-03-13 Impact factor: 6.860
Authors: Celina S Ang; R Katie Kelley; Michael A Choti; David P Cosgrove; Joanne F Chou; David Klimstra; Michael S Torbenson; Linda Ferrell; Timothy M Pawlik; Yuman Fong; Eileen M O'Reilly; Jennifer Ma; Joseph McGuire; Gandhi P Vallarapu; Ann Griffin; Francesco Stipa; Marinela Capanu; Ronald P Dematteo; Alan P Venook; Ghassan K Abou-Alfa Journal: Gastrointest Cancer Res Date: 2013-01
Authors: Elana P Simon; Catherine A Freije; Benjamin A Farber; Gadi Lalazar; David G Darcy; Joshua N Honeyman; Rachel Chiaroni-Clarke; Brian D Dill; Henrik Molina; Umesh K Bhanot; Michael P La Quaglia; Brad R Rosenberg; Sanford M Simon Journal: Proc Natl Acad Sci U S A Date: 2015-10-21 Impact factor: 11.205
Authors: Edward R Kastenhuber; Gadi Lalazar; Shauna L Houlihan; Darjus F Tschaharganeh; Timour Baslan; Chi-Chao Chen; David Requena; Sha Tian; Benedikt Bosbach; John E Wilkinson; Sanford M Simon; Scott W Lowe Journal: Proc Natl Acad Sci U S A Date: 2017-11-21 Impact factor: 11.205
Authors: Kimberly J Riehle; Matthew M Yeh; Jeannette J Yu; Heidi L Kenerson; William P Harris; James O Park; Raymond S Yeung Journal: Mod Pathol Date: 2014-06-13 Impact factor: 7.842
Authors: William J Hammond; Gadi Lalazar; James A Saltsman; Benjamin A Farber; Enrico Danzer; Tshering C Sherpa; Charles D Banda; Jeffrey R Andolina; Sasan Karimi; Cameron W Brennan; Michael S Torbenson; Michael P La Quaglia; Sanford M Simon Journal: Pediatr Blood Cancer Date: 2017-12-29 Impact factor: 3.167
Authors: David G Darcy; Marcus M Malek; Rachel Kobos; David S Klimstra; Ronald DeMatteo; Michael P La Quaglia Journal: J Pediatr Surg Date: 2014-12-10 Impact factor: 2.545
Authors: Suguru Yamashita; Jean-Nicolas Vauthey; Ahmed O Kaseb; Thomas A Aloia; Claudius Conrad; Manal M Hassan; Guillaume Passot; Kanwal P Raghav; Mohamed A Shama; Yun Shin Chun Journal: J Gastrointest Surg Date: 2016-07-25 Impact factor: 3.452